Regenesome Inc. Signs MOU with IDDK Inc. to Launch Joint Research on Exosome Production Systems for Space Environments
Regenesome Inc. (Headquarters: Minato-ku, Tokyo; CEO: Zentaro Sakuma), a subsidiary of Space Seed Holdings Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kengo Suzuki), has signed a memorandum of understanding (MOU) with IDDK Inc. (Headquarters: Koto-ku, Tokyo; CEO: Souichiro Ueno) in December 2024. The agreement marks the beginning of a joint research initiative to develop exosome production systems tailored for space experiments. Together, the companies aim to advance research and development of novel exosome production technologies designed for the unique conditions of space.
Background and Purpose
Space is known for its unique environment, including microgravity and cosmic radiation, which influence cellular behavior and aging processes differently than on Earth. This makes space an invaluable setting for anti-aging research. Regenesome Inc. specializes in exosome research and the development of anti-aging technologies, while IDDK Inc. has a proven track record in developing advanced devices for space biology experiments, such as MicroBioSpaceLAB, which utilizes on-chip microscopic observation technology.
Through this MOU, IDDK Inc. will focus on the development of an exosome experimental system and production system designed for space environments, while Regenesome Inc. will conduct exosome experiments using the system and develop medical technologies based on exosome applications. Both companies are committed to establishing exosome production technologies in space and exploring their potential applications in terrestrial medical and healthcare fields.
Comments from Each Company
Zentaro Sakuma, President and Representative Director, Regenesome Inc.
“We are delighted to explore the new possibilities of exosome production by leveraging the unique conditions of the space environment through this MOU. We look forward to the day when our research outcomes in space contribute to anti-aging technologies and regenerative medicine on Earth.”
Souichiro Ueno, CEO, IDDK Inc.
“We are excited to collaborate with Regenesome Inc. and see how our expertise in space experimental devices can advance exosome research. Together, we aim to develop innovative technologies that harness the unique characteristics of the space environment.”
About IDDK Inc.
Name: IDDK Inc.
Headquarters: 309 Asahi Building, 1-12-8 Tomioka, Koto-ku, Tokyo, Japan
CEO: Souichiro Ueno
Business Activities: Research, development, manufacturing, and sales of microscopic observation devices and related peripheral technologies
Established: June 2017
Website: https://iddk.co.jp
About Regenesome Inc.
Name: Regenesome Inc.
Headquarters: Minato-ku, Tokyo, Japan
CEOs: Kengo Suzuki (CEO) and Zentaro Sakuma (President)
Business Activities: Research, development, and implementation of longevity technologies using nanoparticles and other advanced technologies
Established: July 2024
Website: https://regenesome.com/
About Space Seed Holdings Inc.
With the mission of “Turning Science Fiction into Non-Fiction,” Space Seed Holdings Inc. is a deep-tech venture builder focused on investment, research, and business creation in the space sector. Through initiatives such as the “Fermentation and Longevity Fund” program, the company works to solve societal challenges and develop technologies essential for human habitation in space by 2040, in collaboration with various stakeholders.
https://ss-hd.co.jp/
